Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RETACRIT vs MIRCERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
MIRCERA (methoxy polyethylene glycol-epoetin beta) is a continuous erythropoietin receptor activator that stimulates erythropoiesis by binding to and activating the erythropoietin receptor, leading to increased red blood cell production.
Treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis,Treatment of anemia in HIV-infected patients treated with zidovudine,Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy,Reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery
Treatment of anemia associated with chronic kidney disease in adult patients on dialysis and not on dialysis
50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/d L.
Initial dose 0.6 mcg/kg intravenously or subcutaneously every 2 weeks; for patients not on dialysis, initial dose 1.2 mcg/kg subcutaneously every 2 weeks; target hemoglobin 10-12 g/d L.
Terminal elimination half-life is ~2.5-4.5 hours following intravenous administration; shorter in children; prolonged in hepatic impairment.
Terminal half-life approximately 130-140 hours (about 5-6 days) in patients with chronic kidney disease. This long half-life supports once-monthly dosing. In healthy volunteers, half-life is about 134 hours.
Epoetin alfa-epbx is a protein; metabolism is expected to involve proteolytic degradation via catabolic pathways, similar to endogenous erythropoietin. No specific metabolic enzymes have been identified; clearance is primarily through receptor-mediated uptake and proteolysis.
MIRCERA is primarily eliminated via the reticuloendothelial system and not metabolized by cytochrome P450 enzymes. Minor degradation occurs via proteolysis.
Primarily hepatic metabolism; ~10% excreted unchanged in urine, remainder via feces as metabolites.
Renal (minimal, as MIRCERA is a large glycoprotein that is not significantly filtered by the glomerulus). The majority is eliminated via binding to EPO receptors on target cells followed by internalization and degradation, with less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Primarily binds to transferrin; iron is 100% bound to transferrin after dissociation from complex.
Approximately 50-60% bound to serum proteins, primarily albumin, though binding is reversible and not restrictive.
Vd is approximately 0.067-0.22 L/kg; reflects distribution into plasma and extracellular fluid; limited tissue penetration initially.
Approximately 3.3 L in a 70 kg patient (about 0.047 L/kg), indicating limited distribution primarily to plasma volume. This reflects the large molecular weight of the methoxy polyethylene glycol-epoetin beta conjugate, which restricts extravascular distribution.
Not orally bioavailable; administered intravenously (100% bioavailability for IV route).
Subcutaneous: Approximately 62% relative to intravenous administration. Peak serum concentration occurs 72-120 hours post-dose. Absolute bioavailability not determined due to the drug's endogenous comparators.
For CKD patients, epoetin alfa dosing is independent of GFR; adjust based on hemoglobin response. No specific GFR-based dose adjustments, but start at 50-100 IU/kg three times weekly for dialysis patients.
No dose adjustment required for GFR <30 m L/min; use with caution in patients with chronic kidney disease not on dialysis; monitor hemoglobin closely.
No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment; monitor for adverse effects.
No specific Child-Pugh based dosing; use with caution in severe hepatic impairment; no clinical data available.
0.5-50 IU/kg subcutaneously or intravenously three times weekly, titrated to target hemoglobin. For pediatric CKD, initial dose 50 IU/kg three times weekly.
Not approved for pediatric patients; safety and efficacy not established.
No specific dose adjustment; initiate at lower end of dosing range (50 IU/kg three times weekly) and titrate slowly, monitoring for hypertension and thrombotic events.
No specific dose adjustment for elderly; initial dose based on body weight; monitor hemoglobin and iron status.
WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE. Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of 13 g/d L or greater. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest dose sufficient to reduce the need for red blood cell transfusions. Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid red blood cell transfusions. Use ESAs only for anemia from myelosuppressive chemotherapy. ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure. Discontinue following the completion of a chemotherapy course. Perisurgery: Due to increased risk of deep venous thrombosis (DVT), use prophylactic anticoagulation and consider whether benefit of transfusion reduction outweighs increased risk of post-operative thrombotic/vascular events.
WARNING: ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and tumor progression or recurrence. To reduce these risks, use the lowest dose sufficient to avoid red blood cell transfusion. For patients with chronic kidney disease, use only when hemoglobin is <10 g/d L and individualize dosing to maintain hemoglobin between 10-12 g/d L. Not indicated for use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
Increased mortality, myocardial infarction, stroke, and thromboembolism,Increased risk of thrombosis of vascular access,Increased mortality and/or tumor progression in cancer patients,Hypertension,Seizures,Pure red cell aplasia (PRCA) due to anti-erythropoietin antibodies,Serious allergic reactions,Possible worsening of anemia due to antibody-mediated PRCA,Risk of cardiovascular events when hemoglobin exceeds 11 g/d L,Need for iron supplementation,Monitoring of hemoglobin and blood pressure
Increased mortality and cardiovascular events,Increased risk of thrombotic events and vascular access thrombosis,Increased mortality in cancer patients not receiving myelosuppressive chemotherapy,Hypertension,Seizures,Pure red cell aplasia due to anti-erythropoietin antibodies,Serious allergic reactions including anaphylaxis,Tumor progression in cancer patients
Uncontrolled hypertension,Pure red cell aplasia (PRCA) that begins after treatment with epoetin alfa or other ESAs,Known hypersensitivity to epoetin alfa-epbx or any component of the product
Uncontrolled hypertension,History of serious allergic reactions to MIRCERA or any of its components,Pure red cell aplasia after prior ESA therapy
No specific food interactions. Maintain adequate iron intake; consider dietary sources of iron (e.g., red meat, leafy greens) if not on supplements. No restrictions with alcohol or other foods.
No significant food interactions. However, maintain adequate dietary iron intake as directed. Avoid excessive alcohol, which can affect erythropoiesis.
Retacrit (epoetin alfa-epbx) is a recombinant human erythropoietin. In animal studies, epoetin alfa did not demonstrate teratogenicity at clinically relevant doses. However, there are no adequate and well-controlled studies in pregnant women. Potential fetal risks include hypertension and thromboembolic events secondary to maternal polycythemia. Use during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus.
Pregnancy Category B. Animal studies show no evidence of fetal harm. No adequate human studies in first trimester. Use only if clearly needed. Potential increased risk of thrombotic events in pregnant women.
It is not known whether epoetin alfa is excreted in human milk. Endogenous erythropoietin is present in breast milk. M/P ratio not available. Caution should be exercised when Retacrit is administered to a nursing woman. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child from the drug or underlying maternal condition.
Unknown if excreted in human milk. Caution advised. M/P ratio not determined.
No specific dose adjustments for Retacrit are recommended during pregnancy based on pharmacokinetic changes. However, pregnant women may have increased plasma volume and altered erythropoietin kinetics. The lowest effective dose to gradually increase hemoglobin to the target level (not to exceed 12 g/d L in chronic kidney disease) should be used. Close monitoring of hemoglobin and blood pressure is essential to avoid excessive erythrocytosis and associated risks.
Pharmacokinetic changes in pregnancy may require dose adjustments; however, specific guidelines are lacking. Titrate dose to maintain hemoglobin within target range (typically 10-12 g/d L). Monitor closely for excessive erythropoiesis.
Retacrit (epoetin alfa-epbx) is a biosimilar to Epogen/Procrit. Monitor hemoglobin weekly until stable, then monthly; target Hb 10-12 g/d L. Do not use to replace urgent transfusions. Iron stores must be adequate; check ferritin and transferrin saturation. Increased risk of thrombotic events, especially in patients with cardiovascular disease. Do not shake vial; use one vial per dose; discard unused portion. Administer subcutaneously or intravenously; rotate injection sites.
MIRCERA (methoxy polyethylene glycol-epoetin beta) is a continuous erythropoietin receptor activator (CERA) with a long half-life (approx. 130 hours). Administer intravenously or subcutaneously once every two weeks or once monthly. Monitor hemoglobin weekly until stable, then every 2-4 weeks. Target hemoglobin 10-11 g/d L; do not exceed 12 g/d L to avoid cardiovascular and thromboembolic risks. Dose reductions recommended if HB rises >1 g/d L in 2 weeks. Iron stores must be repleted (transferrin saturation ≥20%, ferritin ≥100 ng/m L). Avoid in patients with uncontrolled hypertension.
This medication helps your body make more red blood cells to treat anemia.,You will have regular blood tests to check your hemoglobin levels and iron stores.,Do not miss scheduled appointments for monitoring; call your doctor if you have symptoms of a blood clot (chest pain, sudden shortness of breath, leg swelling).,It is important to take iron supplements as prescribed while on this medication.,Store Retacrit in the refrigerator; do not freeze or shake the vial.,Report any signs of allergic reaction (rash, itching, swelling).
This medication is given as an injection every 2 weeks or once a month to treat anemia due to chronic kidney disease.,Do not miss doses; if you do, contact your healthcare provider as soon as possible.,Report symptoms of high blood pressure (severe headache, blurred vision, chest pain), blood clots (pain, swelling, redness in legs; sudden shortness of breath), or allergic reactions (rash, itching, difficulty breathing).,Your hemoglobin will be monitored regularly; inform your doctor of any symptoms of anemia (fatigue, pale skin) or excess red blood cells (headache, dizziness).,Iron supplements may be needed; take them exactly as prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RETACRIT vs MIRCERA, answered by our medical review team.
RETACRIT is a Erythropoiesis-Stimulating Agent that works by RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.. MIRCERA is a Erythropoiesis-Stimulating Agent that works by MIRCERA (methoxy polyethylene glycol-epoetin beta) is a continuous erythropoietin receptor activator that stimulates erythropoiesis by binding to and activating the erythropoietin receptor, leading to increased red blood cell production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RETACRIT and MIRCERA depend on the specific clinical indication. These are both Erythropoiesis-Stimulating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RETACRIT is: 50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/d L.. The standard adult dose of MIRCERA is: Initial dose 0.6 mcg/kg intravenously or subcutaneously every 2 weeks; for patients not on dialysis, initial dose 1.2 mcg/kg subcutaneously every 2 weeks; target hemoglobin 10-12 g/d L.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RETACRIT and MIRCERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RETACRIT is classified as Category C. Retacrit (epoetin alfa-epbx) is a recombinant human erythropoietin. In animal studies, epoetin alfa did not demonstrate teratogenicity at clinically relevant doses. However, there . MIRCERA is classified as Category C. Pregnancy Category B. Animal studies show no evidence of fetal harm. No adequate human studies in first trimester. Use only if clearly needed. Potential increased risk of thromboti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.